Green M, Michaels M G, Webber S A, Rowe D, Reyes J
Division of Allergy, Immunology and Infectious Diseases, Children's Hospital of Pittsburgh, Pennsylvania, USA.
Pediatr Transplant. 1999 Nov;3(4):271-81. doi: 10.1034/j.1399-3046.1999.00066.x.
Despite a growing understanding of the pathogenesis and spectrum of Epstein-Barr virus (EBV) and EBV-associated post-transplant lymphoproliferative disease (PTLD) in organ transplant recipients, the optimal management of this complication remains controversial. The absence of comparative data evaluating potential therapeutic strategies explains the lack of uniformly accepted guidelines for the management of PTLD. The purpose of this review is to provide an overview of potential therapies and offer a set of guidelines for the management of EBV-associated PTLD in children.
尽管人们对器官移植受者中爱泼斯坦-巴尔病毒（EBV）及其相关的移植后淋巴细胞增生性疾病（PTLD）的发病机制和范围的认识不断加深，但对这一并发症的最佳管理仍存在争议。缺乏评估潜在治疗策略的比较数据，这解释了为何缺乏统一认可的PTLD管理指南。本综述的目的是概述潜在的治疗方法，并为儿童EBV相关PTLD的管理提供一套指南。
